Bangalore-based Kemwell is planning to develop a biopharmaceutical manufacturing plant in Bangalore at an investment of $50 million (approx Rs 235 crore).
The company has joined hands with German pharmaceutical firm Boehringer Ingelheim for technical and marketing collaboration. Under this, Boehringer Ingelheim will provide technical know-how and marketing support to Kemwell for its contract manufacturing services.
The new facility is likely to be developed on 15,000 sq mtrs which is designed for process development, fermentation, purification and formulation of biologicals for clinical studies. The plant will consist of a cGMP (current Good Manufacturing Practices)-compliant drug manufacturing facility and, a sterile fill and finish facility for drugs. It will house process development laboratories to support production of protein therapeutics.
Source : ProjectsToday
|